flibanserin

Flibanserin can cause weight loss in pre/postmenopausal women with HSDD Premenopausal and postmenopausal women treated with the combined agonist/antagonist flibanserin for hypoactive sexual desire disorder (HSDD) are likely to lose weight, according to a post hoc analysis of five studies.
Taking Sides: Should ob/gyns prescribe flibanserin for their patients?
Taking Sides: Should ob/gyns prescribe flibanserin for their patients?A look at the pros and cons of this new drug for women with low sexual desire.
Flibanserin: Risk potential vs. possible benefitBecause of concerns about adverse effects, training through the Addyi REMS program is required for prescribers and pharmacies that want to participate in the medication use process for this drug.
Top 5 things to know about “female Viagra”FDA’s long-awaited approval of Addyi (flibanserin) to treat hypoactive sexual desire disorder in premenopausal women, is significant for the prescribing community.
Urology Product Preview April 2014Drugs and devices in the pipeline from Astellas Pharma, Medivation, Repros Therapeutics, Metamark Genetics, Argos Therapeutics, S1 Biopharma, Ipsen, Sprout Pharmaceuticals, Antigen Express, Generex Biotechnology, Veloxis Pharmaceuticals, and Absorption Pharmaceuticals.